[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fKjIezHUD0kw-beou9kZtlhX2SMA8-TdSv8nZ-bAFP-A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"The Christie NHS Foundation Trust",[4],100,false,21,8,19646,4,66,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Cancer",10,{"name":18,"count":19},"Lung Cancer",9,{"name":21,"count":22},"Prostate Cancer",5,{"name":24,"count":22},"Breast Cancer",{"name":26,"count":11},"Sarcoma",{"name":28,"count":11},"Ovarian Cancer",{"name":30,"count":31},"Oncology",3,{"name":33,"count":31},"Hodgkin Lymphoma",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06470880","Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy","2026-06","Adaptive Therapy",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06434493","Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma","2028-06-01","Concurrent oral capecitabine chemotherapy",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,79,97,120,138,203,236,268,308,333,355,373,391,409,427,445,463,481,506,524,542,567,602,624,646,676,703,721,746,764,782,808,826,848,874,892,910,928,946,964,982,1000,1024,1048,1066,1103,1138,1160,1178,1204,1222,1247,1274,1306,1324,1342,1365,1389,1407],{"intervention":39,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":73,"PHASE4":75,"NA":77},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":54,"soonestReadout":38},[63],{"nctId":36,"briefTitle":37,"status":64,"phases":65,"primaryCompletion":38,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":71},"NOT_YET_RECRUITING",[48],"2027-06","2024-06",40,[70],"Melanoma",[39,72],"Standard of Care",{"trials":74,"activeCount":58},[],{"trials":76,"activeCount":58},[],{"trials":78,"activeCount":58},[],{"intervention":72,"totalTrials":54,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":91,"PHASE4":93,"NA":95},{"trials":82,"activeCount":58},[],{"trials":84,"activeCount":58},[],{"trials":86,"activeCount":54,"soonestReadout":38},[87],{"nctId":36,"briefTitle":37,"status":64,"phases":88,"primaryCompletion":38,"completion":66,"start":67,"enrollment":68,"conditions":89,"interventions":90},[48],[70],[39,72],{"trials":92,"activeCount":58},[],{"trials":94,"activeCount":58},[],{"trials":96,"activeCount":58},[],{"intervention":44,"totalTrials":54,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":109},{"trials":100,"activeCount":58},[],{"trials":102,"activeCount":58},[],{"trials":104,"activeCount":58},[],{"trials":106,"activeCount":58},[],{"trials":108,"activeCount":58},[],{"trials":110,"activeCount":54,"soonestReadout":43},[111],{"nctId":41,"briefTitle":42,"status":64,"phases":112,"primaryCompletion":43,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},[51],"2029-06-01","2024-11-01",30,[117],"Cholangiocarcinoma",[44,119],"Cisplatin & Gemcitabine intravenous chemotherapy",{"intervention":119,"totalTrials":54,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":132},{"trials":123,"activeCount":58},[],{"trials":125,"activeCount":58},[],{"trials":127,"activeCount":58},[],{"trials":129,"activeCount":58},[],{"trials":131,"activeCount":58},[],{"trials":133,"activeCount":54,"soonestReadout":43},[134],{"nctId":41,"briefTitle":42,"status":64,"phases":135,"primaryCompletion":43,"completion":113,"start":114,"enrollment":115,"conditions":136,"interventions":137},[51],[117],[44,119],{"intervention":139,"totalTrials":11,"cells":140},"cisplatin",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":159,"PHASE3":161,"PHASE4":199,"NA":201},{"trials":142,"activeCount":58},[],{"trials":144,"activeCount":58},[145],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":8,"conditions":152,"interventions":156},"NCT02351765","ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced\u002F Metastatic Biliary Tract Cancers","COMPLETED",[47],"2019-03","2016-01",[153,154,117,155],"Biliary Tract Cancer","Gallbladder Cancer","Ampullary Cancer",[157,158],"Acelarin","Cisplatin",{"trials":160,"activeCount":58},[],{"trials":162,"activeCount":58},[163,177,189],{"nctId":164,"briefTitle":165,"status":166,"phases":167,"start":168,"conditions":169,"interventions":171},"NCT00022178","Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin","UNKNOWN",[49],"1998-12",[170],"Carcinoma of Unknown Primary",[139,172,173,174,175,176],"cyclophosphamide","doxorubicin hydrochloride","epirubicin hydrochloride","fluorouracil","vincristine sulfate",{"nctId":178,"briefTitle":179,"status":166,"phases":180,"start":181,"conditions":182,"interventions":183},"NCT00004887","Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery",[49],"1999-01",[18],[184,139,185,186,187,188],"carboplatin","ifosfamide","mitomycin C","paclitaxel","vinblastine sulfate",{"nctId":190,"briefTitle":191,"status":166,"phases":192,"primaryCompletion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT00055965","Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin",[49],"2006-08","2002-11",400,[18],[184,139,198],"gemcitabine hydrochloride",{"trials":200,"activeCount":58},[],{"trials":202,"activeCount":58},[],{"intervention":172,"totalTrials":204,"cells":205},2,{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":226,"PHASE4":232,"NA":234},{"trials":207,"activeCount":58},[],{"trials":209,"activeCount":58},[],{"trials":211,"activeCount":58},[212],{"nctId":213,"briefTitle":214,"status":215,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":204,"conditions":219,"interventions":221},"NCT01995344","TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment","TERMINATED",[48],"2015-07-24","2014-03-01",[220],"Metastatic Melanoma",[222,223,224,225],"Cyclophosphamide","Fludarabine","Tumour Infiltrating Lymphocytes","Interleukin-2",{"trials":227,"activeCount":58},[228],{"nctId":164,"briefTitle":165,"status":166,"phases":229,"start":168,"conditions":230,"interventions":231},[49],[170],[139,172,173,174,175,176],{"trials":233,"activeCount":58},[],{"trials":235,"activeCount":58},[],{"intervention":175,"totalTrials":204,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":258,"PHASE4":264,"NA":266},{"trials":239,"activeCount":58},[],{"trials":241,"activeCount":58},[],{"trials":243,"activeCount":58},[244],{"nctId":245,"briefTitle":246,"status":148,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT03837977","Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma",[48],"2024-11-26","2018-11-13",58,[30,252],"Neuroendocrine Carcinoma",[254,255,256,257],"Liposomal Irinotecan","Fluorouracil","Folinic Acid","Docetaxel",{"trials":259,"activeCount":58},[260],{"nctId":164,"briefTitle":165,"status":166,"phases":261,"start":168,"conditions":262,"interventions":263},[49],[170],[139,172,173,174,175,176],{"trials":265,"activeCount":58},[],{"trials":267,"activeCount":58},[],{"intervention":269,"totalTrials":204,"cells":270},"Oxaliplatin",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":290,"PHASE4":304,"NA":306},{"trials":272,"activeCount":58},[],{"trials":274,"activeCount":58},[],{"trials":276,"activeCount":58},[277],{"nctId":278,"briefTitle":279,"status":148,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":286},"NCT01225744","Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy",[48],"2013-05","2009-04",47,[285],"Metastatic Colorectal Cancer",[287,288,269,289],"Cetuximab","Irinotecan","UFT",{"trials":291,"activeCount":58},[292],{"nctId":293,"briefTitle":294,"status":148,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT01926236","Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced\u002F Metastatic Biliary Tract Cancers",[49],"2018-01-05","2019-01","2014-02",162,[153,154,117,155],[302,303,269],"L-folinic acid","5 FU",{"trials":305,"activeCount":58},[],{"trials":307,"activeCount":58},[],{"intervention":198,"totalTrials":204,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":329,"NA":331},{"trials":311,"activeCount":58},[],{"trials":313,"activeCount":58},[],{"trials":315,"activeCount":58},[],{"trials":317,"activeCount":58},[318,325],{"nctId":319,"briefTitle":320,"status":166,"phases":321,"start":322,"conditions":323,"interventions":324},"NCT00022009","Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[48,49],"2001-07",[18],[198],{"nctId":190,"briefTitle":191,"status":166,"phases":326,"primaryCompletion":193,"start":194,"enrollment":195,"conditions":327,"interventions":328},[49],[18],[184,139,198],{"trials":330,"activeCount":58},[],{"trials":332,"activeCount":58},[],{"intervention":184,"totalTrials":204,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":351,"NA":353},{"trials":336,"activeCount":58},[],{"trials":338,"activeCount":58},[],{"trials":340,"activeCount":58},[],{"trials":342,"activeCount":58},[343,347],{"nctId":178,"briefTitle":179,"status":166,"phases":344,"start":181,"conditions":345,"interventions":346},[49],[18],[184,139,185,186,187,188],{"nctId":190,"briefTitle":191,"status":166,"phases":348,"primaryCompletion":193,"start":194,"enrollment":195,"conditions":349,"interventions":350},[49],[18],[184,139,198],{"trials":352,"activeCount":58},[],{"trials":354,"activeCount":58},[],{"intervention":173,"totalTrials":54,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":369,"NA":371},{"trials":358,"activeCount":58},[],{"trials":360,"activeCount":58},[],{"trials":362,"activeCount":58},[],{"trials":364,"activeCount":58},[365],{"nctId":164,"briefTitle":165,"status":166,"phases":366,"start":168,"conditions":367,"interventions":368},[49],[170],[139,172,173,174,175,176],{"trials":370,"activeCount":58},[],{"trials":372,"activeCount":58},[],{"intervention":174,"totalTrials":54,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":387,"NA":389},{"trials":376,"activeCount":58},[],{"trials":378,"activeCount":58},[],{"trials":380,"activeCount":58},[],{"trials":382,"activeCount":58},[383],{"nctId":164,"briefTitle":165,"status":166,"phases":384,"start":168,"conditions":385,"interventions":386},[49],[170],[139,172,173,174,175,176],{"trials":388,"activeCount":58},[],{"trials":390,"activeCount":58},[],{"intervention":176,"totalTrials":54,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":405,"NA":407},{"trials":394,"activeCount":58},[],{"trials":396,"activeCount":58},[],{"trials":398,"activeCount":58},[],{"trials":400,"activeCount":58},[401],{"nctId":164,"briefTitle":165,"status":166,"phases":402,"start":168,"conditions":403,"interventions":404},[49],[170],[139,172,173,174,175,176],{"trials":406,"activeCount":58},[],{"trials":408,"activeCount":58},[],{"intervention":185,"totalTrials":54,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":423,"NA":425},{"trials":412,"activeCount":58},[],{"trials":414,"activeCount":58},[],{"trials":416,"activeCount":58},[],{"trials":418,"activeCount":58},[419],{"nctId":178,"briefTitle":179,"status":166,"phases":420,"start":181,"conditions":421,"interventions":422},[49],[18],[184,139,185,186,187,188],{"trials":424,"activeCount":58},[],{"trials":426,"activeCount":58},[],{"intervention":186,"totalTrials":54,"cells":428},{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":441,"NA":443},{"trials":430,"activeCount":58},[],{"trials":432,"activeCount":58},[],{"trials":434,"activeCount":58},[],{"trials":436,"activeCount":58},[437],{"nctId":178,"briefTitle":179,"status":166,"phases":438,"start":181,"conditions":439,"interventions":440},[49],[18],[184,139,185,186,187,188],{"trials":442,"activeCount":58},[],{"trials":444,"activeCount":58},[],{"intervention":187,"totalTrials":54,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":459,"NA":461},{"trials":448,"activeCount":58},[],{"trials":450,"activeCount":58},[],{"trials":452,"activeCount":58},[],{"trials":454,"activeCount":58},[455],{"nctId":178,"briefTitle":179,"status":166,"phases":456,"start":181,"conditions":457,"interventions":458},[49],[18],[184,139,185,186,187,188],{"trials":460,"activeCount":58},[],{"trials":462,"activeCount":58},[],{"intervention":188,"totalTrials":54,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":477,"NA":479},{"trials":466,"activeCount":58},[],{"trials":468,"activeCount":58},[],{"trials":470,"activeCount":58},[],{"trials":472,"activeCount":58},[473],{"nctId":178,"briefTitle":179,"status":166,"phases":474,"start":181,"conditions":475,"interventions":476},[49],[18],[184,139,185,186,187,188],{"trials":478,"activeCount":58},[],{"trials":480,"activeCount":58},[],{"intervention":482,"totalTrials":54,"cells":483},"Nimorazole",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":502,"NA":504},{"trials":485,"activeCount":58},[],{"trials":487,"activeCount":58},[],{"trials":489,"activeCount":58},[],{"trials":491,"activeCount":58},[492],{"nctId":493,"briefTitle":494,"status":148,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT01950689","NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)",[49],"2021-01-07","2014-09-11",338,[500],"Head and Neck Squamous Cell Carcinoma",[482],{"trials":503,"activeCount":58},[],{"trials":505,"activeCount":58},[],{"intervention":302,"totalTrials":54,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":520,"NA":522},{"trials":509,"activeCount":58},[],{"trials":511,"activeCount":58},[],{"trials":513,"activeCount":58},[],{"trials":515,"activeCount":58},[516],{"nctId":293,"briefTitle":294,"status":148,"phases":517,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":518,"interventions":519},[49],[153,154,117,155],[302,303,269],{"trials":521,"activeCount":58},[],{"trials":523,"activeCount":58},[],{"intervention":303,"totalTrials":54,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":538,"NA":540},{"trials":527,"activeCount":58},[],{"trials":529,"activeCount":58},[],{"trials":531,"activeCount":58},[],{"trials":533,"activeCount":58},[534],{"nctId":293,"briefTitle":294,"status":148,"phases":535,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":536,"interventions":537},[49],[153,154,117,155],[302,303,269],{"trials":539,"activeCount":58},[],{"trials":541,"activeCount":58},[],{"intervention":543,"totalTrials":54,"cells":544},"Nivolumab 10 MG\u002FML",{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":563,"NA":565},{"trials":546,"activeCount":58},[],{"trials":548,"activeCount":58},[],{"trials":550,"activeCount":58},[],{"trials":552,"activeCount":58},[553],{"nctId":554,"briefTitle":555,"status":215,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":9,"conditions":559,"interventions":562},"NCT04901988","Circulating Tumour DNA guidEd Therapy for Stage IIB\u002FC mElanoma After surgiCal resecTION",[48,49],"2023-01-30","2021-11-08",[560,561],"Melanoma (Skin)","Melanoma, Stage II",[543],{"trials":564,"activeCount":58},[],{"trials":566,"activeCount":58},[],{"intervention":568,"totalTrials":204,"cells":569},"Avelumab",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":571,"activeCount":58},[],{"trials":573,"activeCount":58},[],{"trials":575,"activeCount":58},[576,587],{"nctId":577,"briefTitle":578,"status":579,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":58,"conditions":583,"interventions":584},"NCT03794596","A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","WITHDRAWN",[48],"2021-02-28","2019-09",[24],[568,585,586],"Aspirin","Lansoprazole",{"nctId":588,"briefTitle":589,"status":579,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":58,"conditions":594,"interventions":595},"NCT04188119","A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer",[48],"2024-09-30","2025-05-31","2023-12-01",[24],[568,585,586],{"trials":597,"activeCount":58},[],{"trials":599,"activeCount":58},[],{"trials":601,"activeCount":58},[],{"intervention":585,"totalTrials":204,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":605,"activeCount":58},[],{"trials":607,"activeCount":58},[],{"trials":609,"activeCount":58},[610,614],{"nctId":577,"briefTitle":578,"status":579,"phases":611,"primaryCompletion":581,"completion":581,"start":582,"enrollment":58,"conditions":612,"interventions":613},[48],[24],[568,585,586],{"nctId":588,"briefTitle":589,"status":579,"phases":615,"primaryCompletion":591,"completion":592,"start":593,"enrollment":58,"conditions":616,"interventions":617},[48],[24],[568,585,586],{"trials":619,"activeCount":58},[],{"trials":621,"activeCount":58},[],{"trials":623,"activeCount":58},[],{"intervention":586,"totalTrials":204,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":627,"activeCount":58},[],{"trials":629,"activeCount":58},[],{"trials":631,"activeCount":58},[632,636],{"nctId":577,"briefTitle":578,"status":579,"phases":633,"primaryCompletion":581,"completion":581,"start":582,"enrollment":58,"conditions":634,"interventions":635},[48],[24],[568,585,586],{"nctId":588,"briefTitle":589,"status":579,"phases":637,"primaryCompletion":591,"completion":592,"start":593,"enrollment":58,"conditions":638,"interventions":639},[48],[24],[568,585,586],{"trials":641,"activeCount":58},[],{"trials":643,"activeCount":58},[],{"trials":645,"activeCount":58},[],{"intervention":287,"totalTrials":204,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":649,"activeCount":58},[],{"trials":651,"activeCount":58},[],{"trials":653,"activeCount":58},[654,658],{"nctId":278,"briefTitle":279,"status":148,"phases":655,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":656,"interventions":657},[48],[285],[287,288,269,289],{"nctId":659,"briefTitle":660,"status":148,"phases":661,"primaryCompletion":662,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":668},"NCT00599833","Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery",[48],"2010-09","2010-10","2007-05",44,[667],"Pancreatic Cancer",[669],"cetuximab",{"trials":671,"activeCount":58},[],{"trials":673,"activeCount":58},[],{"trials":675,"activeCount":58},[],{"intervention":677,"totalTrials":54,"cells":678},"90Y Ibritumomab tiuxetan",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":680,"activeCount":58},[],{"trials":682,"activeCount":58},[],{"trials":684,"activeCount":58},[685],{"nctId":686,"briefTitle":687,"status":148,"phases":688,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT01493479","Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma",[48],"2011-01","2015-11-06","2007-06-06",76,[694],"Follicular Lymphoma",[677,696],"Rituximab",{"trials":698,"activeCount":58},[],{"trials":700,"activeCount":58},[],{"trials":702,"activeCount":58},[],{"intervention":696,"totalTrials":54,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":706,"activeCount":58},[],{"trials":708,"activeCount":58},[],{"trials":710,"activeCount":58},[711],{"nctId":686,"briefTitle":687,"status":148,"phases":712,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":713,"interventions":714},[48],[694],[677,696],{"trials":716,"activeCount":58},[],{"trials":718,"activeCount":58},[],{"trials":720,"activeCount":58},[],{"intervention":722,"totalTrials":54,"cells":723},"PLX3397",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":725,"activeCount":58},[],{"trials":727,"activeCount":58},[],{"trials":729,"activeCount":58},[730],{"nctId":731,"briefTitle":732,"status":148,"phases":733,"primaryCompletion":734,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":739},"NCT02071940","PLX3397 KIT in Acral aNd mucOsal Melanoma",[48],"2021-03-02","2015-10",7,[738],"Malignant Melanoma",[722],{"trials":741,"activeCount":58},[],{"trials":743,"activeCount":58},[],{"trials":745,"activeCount":58},[],{"intervention":288,"totalTrials":54,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":749,"activeCount":58},[],{"trials":751,"activeCount":58},[],{"trials":753,"activeCount":58},[754],{"nctId":278,"briefTitle":279,"status":148,"phases":755,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":756,"interventions":757},[48],[285],[287,288,269,289],{"trials":759,"activeCount":58},[],{"trials":761,"activeCount":58},[],{"trials":763,"activeCount":58},[],{"intervention":289,"totalTrials":54,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":767,"activeCount":58},[],{"trials":769,"activeCount":58},[],{"trials":771,"activeCount":58},[772],{"nctId":278,"briefTitle":279,"status":148,"phases":773,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":774,"interventions":775},[48],[285],[287,288,269,289],{"trials":777,"activeCount":58},[],{"trials":779,"activeCount":58},[],{"trials":781,"activeCount":58},[],{"intervention":783,"totalTrials":54,"cells":784},"Pazopanib",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":786,"activeCount":58},[],{"trials":788,"activeCount":58},[],{"trials":790,"activeCount":58},[791],{"nctId":792,"briefTitle":793,"status":215,"phases":794,"primaryCompletion":795,"completion":795,"start":796,"enrollment":8,"conditions":797,"interventions":800},"NCT02055690","PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +\u002F- Fosbretabulin in Advanced Recurrent Ovarian Cancer",[47,48],"2017-11-24","2014-09",[798,799,28],"Ovarian Neoplasms","Neoplasms, Ovarian",[783,801],"Fosbretabulin",{"trials":803,"activeCount":58},[],{"trials":805,"activeCount":58},[],{"trials":807,"activeCount":58},[],{"intervention":801,"totalTrials":54,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":811,"activeCount":58},[],{"trials":813,"activeCount":58},[],{"trials":815,"activeCount":58},[816],{"nctId":792,"briefTitle":793,"status":215,"phases":817,"primaryCompletion":795,"completion":795,"start":796,"enrollment":8,"conditions":818,"interventions":819},[47,48],[798,799,28],[783,801],{"trials":821,"activeCount":58},[],{"trials":823,"activeCount":58},[],{"trials":825,"activeCount":58},[],{"intervention":827,"totalTrials":54,"cells":828},"temozolomide",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":830,"activeCount":58},[],{"trials":832,"activeCount":58},[],{"trials":834,"activeCount":58},[835],{"nctId":836,"briefTitle":837,"status":166,"phases":838,"start":839,"conditions":840,"interventions":841},"NCT00005054","Temozolomide in Treating Women With Advanced Breast Cancer",[48],"1998-05",[24],[827],{"trials":843,"activeCount":58},[],{"trials":845,"activeCount":58},[],{"trials":847,"activeCount":58},[],{"intervention":849,"totalTrials":54,"cells":850},"Cyclophosphamide 50mg",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":852,"activeCount":58},[],{"trials":854,"activeCount":58},[],{"trials":856,"activeCount":58},[857],{"nctId":858,"briefTitle":859,"status":166,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":8,"conditions":864,"interventions":866},"NCT04262427","The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma",[47,48],"2023-10-28","2024-04-28","2021-04-28",[865],"Metastatic Renal Cell Carcinoma",[849,867],"Pembrolizumab 25 mg\u002F1 ML Intravenous Solution [KEYTRUDA]",{"trials":869,"activeCount":58},[],{"trials":871,"activeCount":58},[],{"trials":873,"activeCount":58},[],{"intervention":867,"totalTrials":54,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":877,"activeCount":58},[],{"trials":879,"activeCount":58},[],{"trials":881,"activeCount":58},[882],{"nctId":858,"briefTitle":859,"status":166,"phases":883,"primaryCompletion":861,"completion":862,"start":863,"enrollment":8,"conditions":884,"interventions":885},[47,48],[865],[849,867],{"trials":887,"activeCount":58},[],{"trials":889,"activeCount":58},[],{"trials":891,"activeCount":58},[],{"intervention":254,"totalTrials":54,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":895,"activeCount":58},[],{"trials":897,"activeCount":58},[],{"trials":899,"activeCount":58},[900],{"nctId":245,"briefTitle":246,"status":148,"phases":901,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":902,"interventions":903},[48],[30,252],[254,255,256,257],{"trials":905,"activeCount":58},[],{"trials":907,"activeCount":58},[],{"trials":909,"activeCount":58},[],{"intervention":256,"totalTrials":54,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":913,"activeCount":58},[],{"trials":915,"activeCount":58},[],{"trials":917,"activeCount":58},[918],{"nctId":245,"briefTitle":246,"status":148,"phases":919,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":920,"interventions":921},[48],[30,252],[254,255,256,257],{"trials":923,"activeCount":58},[],{"trials":925,"activeCount":58},[],{"trials":927,"activeCount":58},[],{"intervention":257,"totalTrials":54,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":931,"activeCount":58},[],{"trials":933,"activeCount":58},[],{"trials":935,"activeCount":58},[936],{"nctId":245,"briefTitle":246,"status":148,"phases":937,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":938,"interventions":939},[48],[30,252],[254,255,256,257],{"trials":941,"activeCount":58},[],{"trials":943,"activeCount":58},[],{"trials":945,"activeCount":58},[],{"intervention":223,"totalTrials":54,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":949,"activeCount":58},[],{"trials":951,"activeCount":58},[],{"trials":953,"activeCount":58},[954],{"nctId":213,"briefTitle":214,"status":215,"phases":955,"primaryCompletion":217,"completion":217,"start":218,"enrollment":204,"conditions":956,"interventions":957},[48],[220],[222,223,224,225],{"trials":959,"activeCount":58},[],{"trials":961,"activeCount":58},[],{"trials":963,"activeCount":58},[],{"intervention":224,"totalTrials":54,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":967,"activeCount":58},[],{"trials":969,"activeCount":58},[],{"trials":971,"activeCount":58},[972],{"nctId":213,"briefTitle":214,"status":215,"phases":973,"primaryCompletion":217,"completion":217,"start":218,"enrollment":204,"conditions":974,"interventions":975},[48],[220],[222,223,224,225],{"trials":977,"activeCount":58},[],{"trials":979,"activeCount":58},[],{"trials":981,"activeCount":58},[],{"intervention":225,"totalTrials":54,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":985,"activeCount":58},[],{"trials":987,"activeCount":58},[],{"trials":989,"activeCount":58},[990],{"nctId":213,"briefTitle":214,"status":215,"phases":991,"primaryCompletion":217,"completion":217,"start":218,"enrollment":204,"conditions":992,"interventions":993},[48],[220],[222,223,224,225],{"trials":995,"activeCount":58},[],{"trials":997,"activeCount":58},[],{"trials":999,"activeCount":58},[],{"intervention":1001,"totalTrials":54,"cells":1002},"Lenalidomide",{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1004,"activeCount":58},[],{"trials":1006,"activeCount":58},[],{"trials":1008,"activeCount":58},[1009],{"nctId":1010,"briefTitle":1011,"status":215,"phases":1012,"completion":1013,"start":1014,"enrollment":54,"conditions":1015,"interventions":1017},"NCT01127542","RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial",[48],"2011-12","2010-05",[1016],"Chronic Lymphocytic Leukaemia",[1001],{"trials":1019,"activeCount":58},[],{"trials":1021,"activeCount":58},[],{"trials":1023,"activeCount":58},[],{"intervention":1025,"totalTrials":54,"cells":1026},"aldesleukin",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1028,"activeCount":58},[],{"trials":1030,"activeCount":58},[],{"trials":1032,"activeCount":58},[1033],{"nctId":1034,"briefTitle":1035,"status":166,"phases":1036,"start":1037,"conditions":1038,"interventions":1040},"NCT00005038","Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer",[48],"1999-06",[1039],"Kidney Cancer",[1025,1041],"histamine dihydrochloride",{"trials":1043,"activeCount":58},[],{"trials":1045,"activeCount":58},[],{"trials":1047,"activeCount":58},[],{"intervention":1041,"totalTrials":54,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":58},[],{"trials":1053,"activeCount":58},[],{"trials":1055,"activeCount":58},[1056],{"nctId":1034,"briefTitle":1035,"status":166,"phases":1057,"start":1037,"conditions":1058,"interventions":1059},[48],[1039],[1025,1041],{"trials":1061,"activeCount":58},[],{"trials":1063,"activeCount":58},[],{"trials":1065,"activeCount":58},[],{"intervention":1067,"totalTrials":204,"cells":1068},"Olaparib",{"EARLY_PHASE1":1069,"PHASE1":1082,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1070,"activeCount":58},[1071],{"nctId":1072,"briefTitle":1073,"status":148,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT02855697","Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer",[46],"2021-12-31","2017-05-26",28,[28],[1067,1080,1081],"Cediranib","Platinum-based Chemotherapy",{"trials":1083,"activeCount":58},[1084],{"nctId":1085,"briefTitle":1086,"status":166,"phases":1087,"primaryCompletion":1088,"completion":1089,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT01460888","Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus",[47],"2015-07","2018-08","2013-07",36,[1093],"Carcinoma of the Oesophagus",[1067],{"trials":1096,"activeCount":58},[],{"trials":1098,"activeCount":58},[],{"trials":1100,"activeCount":58},[],{"trials":1102,"activeCount":58},[],{"intervention":1104,"totalTrials":204,"cells":1105},"AZD6244",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1107,"activeCount":58},[],{"trials":1109,"activeCount":58},[1110,1121],{"nctId":1111,"briefTitle":1112,"status":215,"phases":1113,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1120},"NCT01160926","Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial",[47],"2013-10","2016-11-04","2010-07",31,[1119],"Rectal Cancer",[1104,1080],{"nctId":1122,"briefTitle":1123,"status":148,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":8,"conditions":1127,"interventions":1129},"NCT01146756","MEK Inhibitor and Thoracic Radiotherapy Trial",[47],"2017-02-08","2010-06-04",[1128],"Non Small Cell Lung Cancer",[1104],{"trials":1131,"activeCount":58},[],{"trials":1133,"activeCount":58},[],{"trials":1135,"activeCount":58},[],{"trials":1137,"activeCount":58},[],{"intervention":1080,"totalTrials":204,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1146,"PHASE2":1152,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1141,"activeCount":58},[1142],{"nctId":1072,"briefTitle":1073,"status":148,"phases":1143,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1144,"interventions":1145},[46],[28],[1067,1080,1081],{"trials":1147,"activeCount":58},[1148],{"nctId":1111,"briefTitle":1112,"status":215,"phases":1149,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1150,"interventions":1151},[47],[1119],[1104,1080],{"trials":1153,"activeCount":58},[],{"trials":1155,"activeCount":58},[],{"trials":1157,"activeCount":58},[],{"trials":1159,"activeCount":58},[],{"intervention":157,"totalTrials":54,"cells":1161},{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1170,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1163,"activeCount":58},[],{"trials":1165,"activeCount":58},[1166],{"nctId":146,"briefTitle":147,"status":148,"phases":1167,"primaryCompletion":150,"completion":150,"start":151,"enrollment":8,"conditions":1168,"interventions":1169},[47],[153,154,117,155],[157,158],{"trials":1171,"activeCount":58},[],{"trials":1173,"activeCount":58},[],{"trials":1175,"activeCount":58},[],{"trials":1177,"activeCount":58},[],{"intervention":1179,"totalTrials":54,"cells":1180},"aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1196,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1182,"activeCount":58},[],{"trials":1184,"activeCount":58},[1185],{"nctId":1186,"briefTitle":1187,"status":215,"phases":1188,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1195},"NCT01493453","A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy",[47],"2014-12","2019-06","2008-03",17,[1194],"CD19 Positive Non-Hodgkin Lymphoma",[1179],{"trials":1197,"activeCount":58},[],{"trials":1199,"activeCount":58},[],{"trials":1201,"activeCount":58},[],{"trials":1203,"activeCount":58},[],{"intervention":1081,"totalTrials":54,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":58},[1208],{"nctId":1072,"briefTitle":1073,"status":148,"phases":1209,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1210,"interventions":1211},[46],[28],[1067,1080,1081],{"trials":1213,"activeCount":58},[],{"trials":1215,"activeCount":58},[],{"trials":1217,"activeCount":58},[],{"trials":1219,"activeCount":58},[],{"trials":1221,"activeCount":58},[],{"intervention":1223,"totalTrials":54,"cells":1224},"Optional non-IMP pimonidazole",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1226,"activeCount":58},[],{"trials":1228,"activeCount":58},[],{"trials":1230,"activeCount":58},[],{"trials":1232,"activeCount":58},[],{"trials":1234,"activeCount":58},[],{"trials":1236,"activeCount":58},[1237],{"nctId":1238,"briefTitle":1239,"status":166,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1246},"NCT05702619","Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)",[],"2023-06-30","2021-10-03",60,[21,1245],"Hypoxia",[1223],{"intervention":1248,"totalTrials":54,"cells":1249},"Musculoskeletal health package",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1251,"activeCount":58},[],{"trials":1253,"activeCount":58},[],{"trials":1255,"activeCount":58},[],{"trials":1257,"activeCount":58},[],{"trials":1259,"activeCount":58},[],{"trials":1261,"activeCount":58},[1262],{"nctId":1263,"briefTitle":1264,"status":166,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1273},"NCT04555317","Bone Toxicity Following Pelvic Radiotherapy",[51],"2025-08","2021-05-17",80,[1270,1271,1272],"Gynecologic Cancer","Radiotherapy Side Effect","Fracture",[1248],{"intervention":1275,"totalTrials":54,"cells":1276},"gene expression analysis",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1278,"activeCount":58},[],{"trials":1280,"activeCount":58},[],{"trials":1282,"activeCount":58},[],{"trials":1284,"activeCount":58},[],{"trials":1286,"activeCount":58},[],{"trials":1288,"activeCount":58},[1289],{"nctId":1290,"briefTitle":1291,"status":166,"phases":1292,"primaryCompletion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1303},"NCT00601406","Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer",[51],"2008-02","2006-03",2200,[24,1297,1298,1299,28,1300,21,26,1301,1302],"Cervical Cancer","Endometrial Cancer","Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer","Vaginal Cancer","Vulvar Cancer",[1275,1304,1305],"gene rearrangement analysis","polymorphism analysis",{"intervention":1304,"totalTrials":54,"cells":1307},{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1309,"activeCount":58},[],{"trials":1311,"activeCount":58},[],{"trials":1313,"activeCount":58},[],{"trials":1315,"activeCount":58},[],{"trials":1317,"activeCount":58},[],{"trials":1319,"activeCount":58},[1320],{"nctId":1290,"briefTitle":1291,"status":166,"phases":1321,"primaryCompletion":1293,"start":1294,"enrollment":1295,"conditions":1322,"interventions":1323},[51],[24,1297,1298,1299,28,1300,21,26,1301,1302],[1275,1304,1305],{"intervention":1305,"totalTrials":54,"cells":1325},{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1327,"activeCount":58},[],{"trials":1329,"activeCount":58},[],{"trials":1331,"activeCount":58},[],{"trials":1333,"activeCount":58},[],{"trials":1335,"activeCount":58},[],{"trials":1337,"activeCount":58},[1338],{"nctId":1290,"briefTitle":1291,"status":166,"phases":1339,"primaryCompletion":1293,"start":1294,"enrollment":1295,"conditions":1340,"interventions":1341},[51],[24,1297,1298,1299,28,1300,21,26,1301,1302],[1275,1304,1305],{"intervention":1343,"totalTrials":54,"cells":1344},"ZD4054",{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1351,"PHASE4":1353,"NA":1355},{"trials":1346,"activeCount":58},[],{"trials":1348,"activeCount":58},[],{"trials":1350,"activeCount":58},[],{"trials":1352,"activeCount":58},[],{"trials":1354,"activeCount":58},[],{"trials":1356,"activeCount":58},[1357],{"nctId":1358,"briefTitle":1359,"status":166,"phases":1360,"primaryCompletion":662,"completion":662,"start":1361,"enrollment":115,"conditions":1362,"interventions":1364},"NCT01168141","Window Study of ZD4054 in Metastatic Prostate Cancer",[51],"2009-07",[21,1363],"Metastasis",[1343],{"intervention":1366,"totalTrials":54,"cells":1367},"microarray analysis",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1369,"activeCount":58},[],{"trials":1371,"activeCount":58},[],{"trials":1373,"activeCount":58},[],{"trials":1375,"activeCount":58},[],{"trials":1377,"activeCount":58},[],{"trials":1379,"activeCount":58},[1380],{"nctId":1381,"briefTitle":1382,"status":166,"phases":1383,"primaryCompletion":1384,"start":1385,"enrollment":195,"conditions":1386,"interventions":1387},"NCT00900211","Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX",[],"2012-03","2007-08",[26],[1366,1388],"molecular diagnostic method",{"intervention":1388,"totalTrials":54,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1392,"activeCount":58},[],{"trials":1394,"activeCount":58},[],{"trials":1396,"activeCount":58},[],{"trials":1398,"activeCount":58},[],{"trials":1400,"activeCount":58},[],{"trials":1402,"activeCount":58},[1403],{"nctId":1381,"briefTitle":1382,"status":166,"phases":1404,"primaryCompletion":1384,"start":1385,"enrollment":195,"conditions":1405,"interventions":1406},[],[26],[1366,1388],{"intervention":1408,"totalTrials":54,"cells":1409},"pegvisomant\u002Fplacebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1411,"activeCount":58},[],{"trials":1413,"activeCount":58},[],{"trials":1415,"activeCount":58},[],{"trials":1417,"activeCount":58},[],{"trials":1419,"activeCount":58},[],{"trials":1421,"activeCount":58},[1422],{"nctId":1423,"briefTitle":1424,"status":215,"phases":1425,"completion":1426,"start":1427,"conditions":1428,"interventions":1430},"NCT00468624","Effect of Pegvisomant on GH\u002FIGF-I Relationship in GHD",[51],"2005-07","2004-12",[1429],"Severe Adult Growth Hormone Deficiency",[1408]]